Inventor
David G. Winkler
Inventor
Arlington, MA, US
Overview
Patents· 29 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
A61KPreparations for medical, dental or toiletry purposes20%
C07KPeptides17%
G01NInvestigating or analysing materials by determining their chemical or physical properties13%
C12NMicroorganisms or enzymes11%
A01KAnimal husbandry8%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms6%
C07DHeterocyclic compounds4%
Y02ATechnologies for adaptation to climate change1%
C07CAcyclic or carbocyclic compounds1%
PatentTitleYear
10,675,286Heterocyclic compounds and uses thereof202010,654,816Compounds and compositions for treating conditions associated with NLRP activity2020RE046943Radioprotector compounds and methods20189,791,462'Compositions and methods for increasing bone mineralization'20179,775,844'Heterocyclic compounds and uses thereof'20179,657,095'Antibodies specific for sclerostin and methods for increasing bone mineralization'20179,527,847'Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors'20169,011,856'Antibodies specific for sclerostin and methods for increasing bone mineralization'20158,999,993'Radioprotector compounds and methods'20158,992,911'Antibodies specific for sclerostin and methods for increasing bone mineralization'20158,986,685'Compositions and methods for increasing bone mineralization'20158,828,998'Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors'20148,637,643'Sclerostin binding antibody'20148,563,271'Antibodies specific for sclerostin and methods for increasing bone mineralization'20138,003,108'Sclerostin epitopes'20117,985,834'Compositions and methods for increasing bone mineralization'20117,872,106'Sclerostin-binding antibodies'20117,868,134'Immunogenic peptides derived from sclerostin'20117,758,858'Antibodies associated with alterations in bone density'20107,592,429'Sclerostin-binding antibody'20097,578,999'Antibodies specific for sclerostin'20097,572,899'Compositions and methods for increasing bone mineralization'20097,381,409'Antibodies specific for sclerostin and methods of screening and use therefor'20087,226,902'Ligands for TGF-beta binding proteins and uses thereof'20077,192,583'Methods for modulating bone mineralization'20076,803,453'Antibodies associated with alterations in bone density'20046,495,736'Compositions and methods for increasing bone mineralization'20026,489,445'Polypeptides associated with alterations in bone density'20026,395,511'Nucleic acids encoding a novel family of TGF- binding proteins from humans'2002Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2002–2011Patents assigned to CELLTECH R & D INC (5)· patent assignee history
2002–2010Patents assigned to DARWIN DISCOVERY LTD (5)· patent assignee history
2002–2010Based in Seattle, WA, US· patent location history
2009–2011Patents assigned to AMGEN INC (3)· patent assignee history
2009–2020Based in Arlington, MA, US· patent location history
2011–2017Patents assigned to UCB PHARMA SA (7)· patent assignee history
2014–2020Patents assigned to INFINITY PHARMACEUTICALS INC (4)· patent assignee history
2015–2018Based in Malvern, AU· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UCB PHARMA SA | 7 | 2011–2017 |
| CELLTECH R & D INC | 5 | 2002–2011 |
| DARWIN DISCOVERY LTD | 5 | 2002–2010 |
| INFINITY PHARMACEUTICALS INC | 4 | 2014–2020 |
| AMGEN INC | 3 | 2009–2011 |
Locations
| Location | Patents | Span |
|---|---|---|
| Arlington, Massachusetts, US | 18 | 2009–2020 |
| Seattle, Washington, US | 9 | 2002–2010 |
| Malvern, AU | 2 | 2015–2018 |